Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir
about
Effect of Flap Mutations on Structure of HIV-1 Protease and Inhibition by Saquinavir and DarunavirComputational mutation scanning and drug resistance mechanisms of HIV-1 protease inhibitorsIn vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors.Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypesManaging treatment-experienced pediatric and adolescent HIV patients: role of darunavir.Evaluation of novel protease inhibitors against darunavir-resistant variants of HIV type 1.Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.Both a protective and a deleterious role for the L76V mutation.Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.The L33F darunavir resistance mutation acts as a molecular anchor reducing the flexibility of the HIV-1 protease 30s and 80s loops.Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015
P2860
Q27651021-A562498D-9660-4775-AF54-31A25AA56F5DQ34044221-1D41A847-5A77-445D-A294-F36A51C68CC8Q34296101-F9D67271-ED8B-4F8F-BB0C-EEE3E662BF7DQ34563005-96AD473B-2DDD-47F2-BAB4-B94852C14728Q37298255-A007DBC3-4BB8-47C1-96DA-07D3DD5A4332Q40376538-5C1EF906-22F4-436C-BD63-BA134D1929B1Q42120771-2BBEA9C9-F7CF-47E2-B581-91C71641FF45Q43153499-A70B97A4-F900-428A-95FA-1F6DDB643F56Q43601186-68C47DFB-1ADC-44DC-8D87-4D6E1B3E8B13Q45345083-7E83CCF9-0D3F-49CB-9FAF-AD45FEE69B81Q52671185-E1B70FBF-005A-4EDA-84CF-A3CAD8261FDDQ57180790-26923C6E-5993-4DBF-B2EE-F1A2E2895FE8
P2860
Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Factors associated with the se ...... treatment failure on darunavir
@ast
Factors associated with the se ...... treatment failure on darunavir
@en
type
label
Factors associated with the se ...... treatment failure on darunavir
@ast
Factors associated with the se ...... treatment failure on darunavir
@en
prefLabel
Factors associated with the se ...... treatment failure on darunavir
@ast
Factors associated with the se ...... treatment failure on darunavir
@en
P2093
P2860
P50
P356
P1476
Factors associated with the se ...... treatment failure on darunavir
@en
P2093
Ana Canestri
Anne-Geneviève Marcelin
Cathia Soulié
Christine Blanc
Marc Wirden
Rachid Agher
Sidonie Lambert-Niclot
Vincent Calvez
P2860
P304
P356
10.1128/AAC.00909-07
P407
P577
2007-11-26T00:00:00Z